Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Mattias Ohlsson

Mattias Ohlsson


Mattias Ohlsson

Human Leukocyte Antigen-Based Risk Stratification in Heart Transplant Recipients-Implications for Targeted Surveillance


  • Johan Nilsson
  • David Ansari
  • Mattias Ohlsson
  • Peter Höglund
  • Ann Sofie Liedberg
  • J. Gustav Smith
  • Pierre Nugues
  • Bodil Andersson

Summary, in English

Background Human leukocyte antigen (HLA) matching isn't routinely performed in heart transplantation. Novel allograft perfusion methods may make HLA matching feasible. The purpose of this study is to reexamine whether HLA mismatch may be used in risk stratification to improve outcomes in heart transplantation. Methods and Results We analyzed 34 681 recipients undergoing heart transplantation between 1987 and 2013. We used HLAMatchmaker to quantify HLA eplet mismatches and Cox regression for analysis of time to graft loss. Recipients with 4 mismatched HLA-DR/DQ alleles and >40 eplets reached an adjusted hazard ratio (HR) for graft loss of 1.17 (95% CI 1.07-1.28) and 1.11 (95% CI 1.03-1.21), respectively. We found significant interaction between recipient age and numbers of HLA-DR/DQ allele and eplet mismatches resulting in an adjusted HR of 1.78 (95% 1.13-2.80) and 1.82 (95% CI, 1.23-2.70), respectively. HR for both interaction terms was 0.99 (95% CI, 0.98-1.00). Risk of graft loss was more pronounced after 1 year, where recipient <40 years with 4 mismatched HLA-DR/DQ alleles and >40 eplets had an adjusted HR of 1.51 (95% CI 1.12-2.03) and 1.32 (95% CI 1.02-1.70), respectively. Pre-sensitized recipients with panel reactive antibodies >10% had an adjusted HR=1.27 (95% CI 1.16-1.40) for graft loss within 1 year but not thereafter. HLA eplet mismatch was independent of panel reactive antibodies on reduction of graft loss within and after 1 year, P (interaction)=0.888 and 0.389. Conclusions HLA mismatch may be used in risk stratification for intensified post-transplant surveillance and therapy.


  • Thoracic Surgery
  • eSSENCE: The e-Science Collaboration
  • Artificial Intelligence in CardioThoracic Sciences (AICTS)
  • Heart and Lung transplantation
  • Computational Biology and Biological Physics
  • Division of Clinical Chemistry and Pharmacology
  • Division of Microbiology, Immunology and Glycobiology - MIG
  • Heart Failure and Mechanical Support
  • Cardiology
  • EpiHealth: Epidemiology for Health
  • EXODIAB: Excellence in Diabetes Research in Sweden
  • Department of Computer Science
  • ELLIIT: the Linköping-Lund initiative on IT and mobile communication
  • Surgery (Lund)
  • Robotics and Semantic Systems

Publishing year





Journal of the American Heart Association





Document type

Journal article




  • Cardiac and Cardiovascular Systems


  • HLAMatchmaker
  • human leukocyte antigen
  • rejection
  • risk stratification
  • survival
  • transplantation



Research group

  • Artificial Intelligence in CardioThoracic Sciences (AICTS)
  • Heart and Lung transplantation
  • Heart Failure and Mechanical Support


  • ISSN: 2047-9980